NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 (titrated to a subject's optimal dose in the range of 25 to 75 mg) administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.

Clinical Trial Description

This is a Phase 2, randomized, double-blind, placebo-controlled, dose-titration study to evaluate the efficacy, safety, and tolerability of NBI-98854 (titrated to subject's optimal dose in the range of 25 to 75 mg) compared to placebo, administered once daily (q.d.) for a total of 6 weeks of treatment. Approximately 90 medically stable male and female subjects with one of the following clinical diagnoses will be enrolled: schizophrenia or schizoaffective disorder with neuroleptic-induced TD; mood disorder with neuroleptic-induced TD; or gastrointestinal disorder with metoclopramide-induced TD.

For subjects randomized to active treatment, the starting dose will be 25 mg NBI 98854, which may be escalated in increments of 25 mg every 2 weeks to a maximum of 75 mg to achieve an optimal dose of NBI-98854 for each subject ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01733121
Study type	Interventional
Source	Neurocrine Biosciences
Contact
Status	Completed
Phase	Phase 2
Start date	December 2012
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02840760` - Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.	N/A
Completed	`NCT01688037` - NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)	Phase 2
Completed	`NCT01391390` - Melatonin Treatment for Tardive Dyskinesia in Schizophrenia	N/A
Withdrawn	`NCT03254186` - Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia	Phase 2/Phase 3
Completed	`NCT02291861` - Addressing Involuntary Movements in Tardive Dyskinesia	Phase 3
Completed	`NCT02274558` - A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia	Phase 3
Completed	`NCT02198794` - Reducing Involuntary Movements in Participants With Tardive Dyskinesia	Phase 3
Completed	`NCT01467089` - The Assessment of Movement Disorders Utilizing Live Two-Way Video	N/A
Completed	`NCT04794413` - Pimavanserin Treatment in TS	Early Phase 1
Recruiting	`NCT06011408` - Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes	N/A
Recruiting	`NCT05859698` - Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia	Phase 4
Active, not recruiting	`NCT02252380` - ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders	N/A
Terminated	`NCT00917293` - Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia	Phase 2
Completed	`NCT01543321` - Xenazine in Late Dyskinetic Syndrome With Neuroleptics	Phase 3
Completed	`NCT02405091` - Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia	Phase 3
Completed	`NCT03176771` - Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia	Phase 2/Phase 3
Terminated	`NCT02524886` - Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia	N/A
Completed	`NCT02195700` - Aim to Reduce Movements in Tardive Dyskinesia	Phase 2/Phase 3
Completed	`NCT02736955` - Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia	Phase 3
Completed	`NCT03497013` - Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia	N/A